Deleted Tweets From Scott Gottlieb, R-D.C.

Even when Essure is no longer sold, the #FDA will remain vigilant in protecting patients who’ve already had this device implanted. We’ll continue to monitor adverse events and publicly communicate any new safety findings on this - and any other device. https://t.co/H3SSwXIHnP

212 people are sick, 34 hospitalized in 44 states in outbreaks of Salmonella infections linked to backyard flocks. https://t.co/kJ3uFFvy29 https://t.co/D7YF7IJbys

THREAD: REGULATORY NEWS - Today, the #FDA announced several new and key actions pertaining to bulk drug substances for the compounding of human drug products. https://t.co/lEZZ3neP4N

RT @SGottliebFDA: In today’s #FDA #SUNDAYTWEETORIAL I’m going to talk about the initiatives we have underway to prioritize and enhanc… https://t.co/ce9fqZmo04

RT @medpagetoday: .@US_FDA Commissioner @SGottliebFDA pitched his agency's plan for increasing competition in the biosimilar market.… https://t.co/MH9Mll6gXF

#FDA’s new actions on compounding underscore our focus on protecting patients while making sure we have an enduring framework for better compounding that’s well informed by input from the clinical community. https://t.co/lEZZ3neP4N

RT @US_FDA: FDA has awarded four grants totaling $600k to two companies developing animal drugs for often-overlooked species or… https://t.co/2luBQYEAL9

RT @FDAMedia: FDA continues taking key actions on bulk drug substances used for compounding to advance the regulatory framework g… https://t.co/d11rFSciQR

FOOD RECALL: Mondelez Global LLC is recalling Ritz sandwiches and Ritz bits cheese products because an ingredient could be contaminated with Salmonella. There are no related illnesses. FDA is investigating and will provide more info as we learn more https://t.co/tcs4DDO6zu https://t.co/fc3B4es66z

RT @FDAOncology: #FDAOncology Director Dr. Richard Pazdur with our 2018 OCE Summer Scholars. Read why Dr. Pazdur started the program… https://t.co/VEZ0P8QG5a

Today we announced we’ll hold a Part 15 Public Hearing Sept. 4 to get input on how to facilitate greater availability of #biosimilar and interchangeable products, with a focus on balancing competition and innovation in the biologics market.  https://t.co/dh4XHLMeoR 1/2 https://t.co/tRgh8MVVEZ

As part of our recent #Biosimilars Action Plan, we committed to engaging in a public dialogue to gain feedback from patients, providers and industry about what additional policy steps #FDA should consider as we seek to enhance our biosimilars program https://t.co/DHLMMFN2Zx 2/2

RT @FDAMedia: FDA In Brief: FDA launches new campaign to advance ongoing efforts to recruit and retain a world-class workforce de… https://t.co/WfqHGTkGoN

RT @michaelcburgess: Today @housecommerce #SubHealth is continuing our check up on the implementation of 21st Century Cures Act. I’m loo… https://t.co/CV3iT9K5Lj

RT @SGottliebFDA: To advance development of generic drugs #FDA issued 43 product-specific guidances to lay out the path for copying i… https://t.co/FGucK7iHT1

RT @FDA_Drug_Info: #FDA publishes a list of valsartan-containing products not part of the recall: https://t.co/e1RxlE5CZi.

THREAD: Today I testified at the @HouseCommerce #subhealth hearing on #Cures that #FDA is taking steps to modernize clinical trials https://t.co/58y3SfLNIS

One big step we are taking is addressing surrogate endpoints which are used when clinical outcomes, like a stroke, take long to study or when the clinical benefit of improving the surrogate endpoint, like blood pressure, is well understood.

We’re seeing advances in oncology with the use of innovative endpoints for accelerated and traditional approvals. The use of surrogates for cancer can put promising treatments into the hands of patients years before they would’ve been available using previous endpoints.

RT @FDASpox: Today @US_FDA published a Surrogate Endpoint Table, a list of surrogate endpoints which were the basis of approval… https://t.co/kS3BjE5CP2

Even when Essure is no longer sold, the #FDA will remain vigilant in protecting patients who’ve already had this device implanted. We’ll continue to monitor adverse events and publicly communicate any new safety findings on this - and any other device. https://t.co/H3SSwXIHnP

212 people are sick, 34 hospitalized in 44 states in outbreaks of Salmonella infections linked to backyard flocks. https://t.co/kJ3uFFvy29 https://t.co/D7YF7IJbys

THREAD: REGULATORY NEWS - Today, the #FDA announced several new and key actions pertaining to bulk drug substances for the compounding of human drug products. https://t.co/lEZZ3neP4N

RT @SGottliebFDA: In today’s #FDA #SUNDAYTWEETORIAL I’m going to talk about the initiatives we have underway to prioritize and enhanc… https://t.co/ce9fqZmo04

RT @medpagetoday: .@US_FDA Commissioner @SGottliebFDA pitched his agency's plan for increasing competition in the biosimilar market.… https://t.co/MH9Mll6gXF

#FDA’s new actions on compounding underscore our focus on protecting patients while making sure we have an enduring framework for better compounding that’s well informed by input from the clinical community. https://t.co/lEZZ3neP4N

RT @US_FDA: FDA has awarded four grants totaling $600k to two companies developing animal drugs for often-overlooked species or… https://t.co/2luBQYEAL9

RT @FDAMedia: FDA continues taking key actions on bulk drug substances used for compounding to advance the regulatory framework g… https://t.co/d11rFSciQR

FOOD RECALL: Mondelez Global LLC is recalling Ritz sandwiches and Ritz bits cheese products because an ingredient could be contaminated with Salmonella. There are no related illnesses. FDA is investigating and will provide more info as we learn more https://t.co/tcs4DDO6zu https://t.co/fc3B4es66z

RT @FDAOncology: #FDAOncology Director Dr. Richard Pazdur with our 2018 OCE Summer Scholars. Read why Dr. Pazdur started the program… https://t.co/VEZ0P8QG5a

Today we announced we’ll hold a Part 15 Public Hearing Sept. 4 to get input on how to facilitate greater availability of #biosimilar and interchangeable products, with a focus on balancing competition and innovation in the biologics market.  https://t.co/dh4XHLMeoR 1/2 https://t.co/tRgh8MVVEZ

As part of our recent #Biosimilars Action Plan, we committed to engaging in a public dialogue to gain feedback from patients, providers and industry about what additional policy steps #FDA should consider as we seek to enhance our biosimilars program https://t.co/DHLMMFN2Zx 2/2

RT @FDAMedia: FDA In Brief: FDA launches new campaign to advance ongoing efforts to recruit and retain a world-class workforce de… https://t.co/WfqHGTkGoN

RT @michaelcburgess: Today @housecommerce #SubHealth is continuing our check up on the implementation of 21st Century Cures Act. I’m loo… https://t.co/CV3iT9K5Lj

RT @SGottliebFDA: To advance development of generic drugs #FDA issued 43 product-specific guidances to lay out the path for copying i… https://t.co/FGucK7iHT1

RT @FDA_Drug_Info: #FDA publishes a list of valsartan-containing products not part of the recall: https://t.co/e1RxlE5CZi.

THREAD: Today I testified at the @HouseCommerce #subhealth hearing on #Cures that #FDA is taking steps to modernize clinical trials https://t.co/58y3SfLNIS

One big step we are taking is addressing surrogate endpoints which are used when clinical outcomes, like a stroke, take long to study or when the clinical benefit of improving the surrogate endpoint, like blood pressure, is well understood.

We’re seeing advances in oncology with the use of innovative endpoints for accelerated and traditional approvals. The use of surrogates for cancer can put promising treatments into the hands of patients years before they would’ve been available using previous endpoints.

RT @FDASpox: Today @US_FDA published a Surrogate Endpoint Table, a list of surrogate endpoints which were the basis of approval… https://t.co/kS3BjE5CP2